publication date: Nov. 8, 2019

NCI Trials

NCI Trials for November 2019

The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month. 

For further information, contact the principal investigator listed.


Phase I – 10273

A Phase I Study of M3814 in Combination with MEC in Patients with Relapsed or Refractory Acute Myeloid Leukemia

City of Hope Comprehensive Cancer Center LAO

Jonas, Brian Andrew

(916) 734-3772


Phase I – NRG-GY022

Assessment of Carboplatin Clearance Predictors: A PK Study on NCI-Sponsored Clinical Trials or Standard of Care Treatments Using Carboplatin

NRG Oncology

Taylor, Sarah E.

(412) 641-5468


Phase I/II – 10287

A Randomized Phase I/II Trial of Fulvestrant and Abemaciclib in Combination with Copanlisib (FAC) Versus Fulvestrant and Abemaciclib Alone (FA) for Endocrine-Resistant, Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer (FAC vs FA)

Duke University –
Duke Cancer Institute LAO

Ma, Cynthia Xiuguang

(314) 362-9383


Phase II – EA4181

A Randomized 3-Arm Phase II Study Comparing 1.) Bendamustine, Rituximab and High Dose Cytarabine (BR/CR) 2.) Bendamustine, Rituximab, High Dose Cytarabine and Acalabrutinib (BR/CR-A), and 3.) Bendamustine, Rituximab and Acalabrutinib (BR-A) in Patients <= 70 Years Old with Untreated Mantle Cell Lymphoma

ECOG-ACRIN Cancer Research Group

Wagner-Johnston, Nina Delaney

(410) 955-8839


Phase II – NRG-GY021

A Phase II Randomized Trial of Olaparib Versus Olaparib Plus Tremelimumab in Platinum-Sensitive Recurrent Ovarian Cancer

NRG Oncology

Adams, Sarah F.

Continue reading NCI Trials for November 2019

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.